How Do Immunomodulatory Agents Support COVID-19 Treatment?

by Application of Green Reagents in Pharmaceutical Synthesis on Apr 15th, 2025 09:55 AM

[size=2][font=Verdana, Arial, Helvetica, sans-serif]COVID-19 induces hyperinflammatory responses, necessitating immunomodulatory agents to mitigate excessive immune reactions.[/font][/size]
[size=3][font=MontserratRegular, Arial, sans-serif, serif][b]Corticosteroids (Dexamethasone)[/b][/font][/size]
[color=#233ca1]Dexamethasone[/color] is widely used to reduce inflammation in severe COVID-19 cases, particularly in patients requiring oxygen therapy or mechanical ventilation. It helps decrease mortality rates by modulating cytokine storm effects.
[size=3][font=MontserratRegular, Arial, sans-serif, serif][b]Baricitinib (Olumiant)[/b][/font][/size]
[size=3][font=MontserratRegular, Arial, sans-serif, serif]Baricitinib[/font][/size], a Janus kinase (JAK) inhibitor, reduces inflammation by blocking the JAK-STAT signaling pathway. It is administered orally in hospitalized patients requiring supplemental oxygen or non-invasive ventilation.